Tuberculosis Elimination and Laboratory Cooperative Agreement
Closed Posted
- Opportunity number
- CDC-RFA-PS-25-0003
- Agency
-
Centers for Disease Control and Prevention
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- Other
- County Governments
- City/Township Governments
- Unrestricted
- State Governments
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Centers for Disease Control and Prevention (CDC) is seeking applicants for the Tuberculosis Elimination and Laboratory Cooperative Agreement (CDC-RFA-PS-25-0003). This 5-year funding opportunity aims to support state, local, and territorial tuberculosis (TB) programs in preventing, controlling, and eliminating TB in the United States. Key activities include diagnosis and treatment of TB disease, contact investigations, targeted testing and treatment of latent TB infection (LTBI), program planning and evaluation, surveillance, human resource development, and laboratory strengthening. Expected outcomes include decreases in TB incidence, increases in patient treatment completion rates, and improvements in surveillance data quality and laboratory turnaround times.
The total funding available is $374,456,055, with an estimated 57 cooperative agreements to be awarded. The average one-year award amount is $1,313,880. This funding opportunity is authorized under the Public Health Service Act and supports the Healthy People 2030 Immunization and Infectious Diseases objectives. The application deadline is October 4, 2024, and the estimated award date is December 1, 2024.
Synopsis
2 versions
Update #2 · Latest ·
This opportunity is being reopened from 9/27/24 - 10/4/24 to allow applicants to resubmit applications who were unsuccessful in submitting the required attachments, including Attachment A: TB Prevention, Control and Elimination Plan and Attachment B: Evidence of Jurisdiction Infrastructure. - CDC announces available Fiscal Year (FY) 2025 funds to complement tuberculosis (TB) prevention and control activities and laboratory services at state and local levels to reduce TB morbidity and mortality. The goal of this funding is to prevent transmission of M. tuberculosis (TB) and prevent progression from latent TB infection to active TB disease. Funding levels are determined by formulas reflecting TB disease incidence, case complexity, program performance, and laboratory workload data. Strategies and activities include diagnosis/treatment of persons with TB disease and persons with latent TB infection (LTBI); examination of immigrants and refugees who have an overseas B classification for TB; targeted testing for, and treatment of, LTBI; program planning, evaluation, and improvement; epidemiologic surveillance and response; human resource development and partnership activities; and public health laboratory strengthening. Expected outcomes include (but are not limited to) decreases in TB incidence; increases in patients completing treatment within 12 months; increases in HIV and drug susceptibility testing in TB cases; increases in LTBI testing and treatment completion rates of those recommended for treatment; increases in accuracy and completeness of surveillance, genotyping, and whole-genome sequencing data; improvement in turnaround times for specimen receipt and laboratory testing and implementation of TB elimination plans.
Update #1 ·
CDC announces available Fiscal Year (FY) 2025 funds to complement tuberculosis (TB) prevention and control activities and laboratory services at state and local levels to reduce TB morbidity and mortality. The goal of this funding is to prevent transmission of M. tuberculosis (TB) and prevent progression from latent TB infection to active TB disease. Funding levels are determined by formulas reflecting TB disease incidence, case complexity, program performance, and laboratory workload data. Strategies and activities include diagnosis/treatment of persons with TB disease and persons with latent TB infection (LTBI); examination of immigrants and refugees who have an overseas B classification for TB; targeted testing for, and treatment of, LTBI; program planning, evaluation, and improvement; epidemiologic surveillance and response; human resource development and partnership activities; and public health laboratory strengthening. Expected outcomes include (but are not limited to) decreases in TB incidence; increases in patients completing treatment within 12 months; increases in HIV and drug susceptibility testing in TB cases; increases in LTBI testing and treatment completion rates of those recommended for treatment; increases in accuracy and completeness of surveillance, genotyping, and whole-genome sequencing data; improvement in turnaround times for specimen receipt and laboratory testing and implementation of TB elimination plans.
Files
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity